What's Happening?
Lantern Pharma Inc., a precision oncology company, has announced promising preliminary results from its Phase 2 HARMONIC™ clinical trial for the investigational drug LP-300. The trial focuses on patients with EGFR Exon 21 L858R-mutant non-small cell lung
cancer (NSCLC) who have progressed after tyrosine kinase inhibitor (TKI) therapy. The data indicates an 8.3-month median progression-free survival (PFS) for patients receiving LP-300 in combination with carboplatin and pemetrexed. Lantern Pharma plans to discuss protocol amendments with the U.S. Food and Drug Administration (FDA) in a Type C meeting scheduled for mid-May 2026. These amendments aim to refine the trial design to better target patients who are most likely to benefit from the treatment.
Why It's Important?
The findings from the HARMONIC™ trial are significant as they offer a potential new treatment option for a subgroup of lung cancer patients with limited therapeutic choices. The EGFR Exon 21 L858R mutation accounts for a substantial portion of EGFR-mutant NSCLC cases, which are challenging to treat, especially after TKI therapy failure. The promising PFS results suggest that LP-300 could provide a meaningful clinical benefit without adding significant toxicity. This development could impact the treatment landscape for NSCLC, offering hope to patients with poor prognoses and limited options.
What's Next?
Lantern Pharma is seeking FDA feedback on proposed amendments to the HARMONIC™ trial, which include focusing future enrollment on patients with the L858R mutation, converting the trial to a single-arm study, and increasing the number of treatment cycles. These changes aim to optimize the trial's design and improve patient outcomes. The company is also exploring collaboration opportunities to maximize the commercial potential of LP-300 across different regions, particularly in Asia, where the L858R mutation is more prevalent.
